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Abstract 
Ayahuasca is an Amazonian psychotropic plant tea typically obtained from two 
plants, Banisteriopsis caapi and Psychotria viridis. It contains the psychedelic 5-HT2A 
and sigma-1 agonist N,N-dimethyltryptamine (DMT) plus β-carboline alkaloids with 
monoamine-oxidase (MAO)-inhibiting properties. Although the psychoactive effects of 
ayahuasca have commonly been attributed solely to agonism at the 5-HT2A receptor, the 
molecular target of classical psychedelics, this has not been tested experimentally. Here 
we wished to study the contribution of the 5-HT2A receptor to the neurophysiological 
and psychological effects of ayahuasca in humans. We measured drug-induced changes 
in spontaneous brain oscillations and subjective effects in a double-blind randomized 
placebo-controlled study involving the oral administration of ayahuasca (0.75 mg 
DMT/kg body weight) and the 5-HT2A antagonist ketanserin (40 mg). Twelve healthy, 
experienced psychedelic users (5 females) participated in four experimental sessions in 
which they received the following drug combinations: placebo+placebo, 
placebo+ayahuasca, ketanserin+placebo and ketanserin+ayahuasca. Ayahuasca induced 
EEG power decreases in the delta, theta and alpha frequency bands. Current density in 
alpha-band oscillations in parietal and occipital cortex was inversely correlated with the 
intensity of visual imagery induced by ayahuasca. Pretreatment with ketanserin 
inhibited neurophysiological modifications, reduced the correlation between alpha and 
visual effects, and attenuated the intensity of the subjective experience. These findings 
suggest that despite the chemical complexity of ayahuasca, 5-HT2A activation plays a 
key role in the neurophysiological and visual effects of ayahuasca in humans. 
 
Key words: Ayahuasca, serotonin-2A receptor, ketanserin, subjective effects, 
neurophysiological effects, human  
This is an author-edited version of the accepted manuscript published in European Neuripsychofarmachology. The 
final publication is available at Elsevier via http://dx.doi.org/10.1016/j.euroneuro.2016.03.012 
 
 3 
Introduction 
Ayahuasca is a psychoactive plant tea used traditionally by the indigenous 
peoples of the Upper Amazon (Schultes, 1980) and in more recent times by healers and 
members of religious syncretic groups (Tupper, 2008). This tea is receiving increased 
attention from the general public and biomedical researchers (Frood, 2015). It has been 
used to help treat addiction (Fernández et al., 2014), and recent open-label studies have 
shown preliminary evidence of rapid and lasting antidepressant effects after a single 
dose (Osório et al., 2015; Sanches et al., 2015). 
Although there are many variations in the preparation of the tea, the common 
ingredient is the malpighiaceous vine Banisteriopsis caapi. This plant is rich in β-
carboline alkaloids, mainly harmine, harmaline and tetrahydroharmine (THH) (Riba, 
2003). These alkaloids show monoamine-oxidase inhibiting properties (N S Buckholtz 
and Boggan, 1977), while THH is also a serotonin reuptake inhibitor (N. S. Buckholtz 
and Boggan, 1977). In addition to B. caapi, other admixture plants are frequently used 
in the preparation of ayahuasca. One of the most common in the context of modern use 
is Psychotria viridis. The leaves of this plant are rich in the psychedelic indole N,N-
dimethyltryptamine or DMT (Riba, 2003). 
DMT is structurally related to the neurotransmitter serotonin (5-
hydroxytryptamine; 5-HT) and shows agonist activity at the 5-HT2A and 5-HT1A 
receptors. DMT also acts as an agonist at the trace amine associated receptor (TAAR) 
(Bunzow et al., 2001) and it is a substrate of the serotonin and the vesicle monoamine 
transporters (Cozzi et al., 2009). It has been suggested that using these uptake 
mechanisms, intracellular concentrations could reach higher values than in plasma and 
interact with the intracellular sigma-1 receptor (Fontanilla et al., 2009). This receptor 
modulates the activity of many other proteins, conferring stability against cellular stress, 
and promoting brain plasticity (Chu and Ruoho, 2016; Tsai et al., 2009).  
When administered to humans parenterally, DMT induces intense modifications 
of the ordinary state of awareness with intense visual effects, but it is devoid of 
psychoactivity when taken orally (Riba et al., 2015) due to degradation by MAO 
(Suzuki et al., 1981), and cytochrome-dependent mechanisms (Riba et al., 2015). The 
presence of the MAO-inhibiting β-carbolines in ayahuasca prevents is enzymatic 
degradation and allows its oral bioavailability (Riba et al., 2003a). 
In previous studies by our group, we found ayahuasca to induce a pattern of 
psychedelic effects with a slower onset and longer duration than those induced by DMT 
(Dos Santos et al., 2011; Riba et al., 2003a, 2001b). Neurophysiologically, ayahuasca 
induces broad-band power decreases in spontaneous electrical brain oscillations (Riba et 
al., 2002a) and associated reductions in intracerebral current source density (CSD) in 
certain brain areas (Riba et al., 2004). These reductions are particularly strong for 
oscillations in the alpha band of the EEG, with CSD reductions over the posterior visual 
cortex, an effect thought to reflect increased cortical excitability (Romei et al., 2008b). 
Analogous findings in the range of the alpha band have also been observed using 
magnetoencephalography and the psychedelic and serotonin-2A receptor agonist 
psilocybin (Muthukumaraswamy et al., 2013). 
The aim of this study was to assess the contribution of serotonin-2A receptor to 
the neurophysiological and psychological effects of ayahuasca. We postulated that 
despite the combination of various pharmacological mechanisms in ayahuasca, the 
general psychedelic effects and decreases in current density depend on activation of the 
5-HT2A receptor. To test this hypothesis, we studied the interaction of a medium dose of 
ayahuasca (Riba et al., 2001b) and ketanserin, a 5-HT2A receptor antagonist, in a group 
of experienced psychedelic users in a laboratory setting.  
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Experimental Procedures  
Participants  
 For ethical reasons, we only recruited individuals with prior experience with 
psychedelics. We wanted to avoid introducing drug-naive individuals to psychedelics, 
and to make sure that volunteers would be familiar with the modified state of 
consciousness induced by these drugs. We therefore contacted psychedelic drug users 
and informed them about the goals of the study, the nature of ayahuasca, its 
psychological effects, and the potential adverse effects described in the literature for 
psychedelics. We recruited a group of 12 healthy volunteers (5 females, 7 males) with 
previous experience with psychedelic drugs (10 times or more). Despite their experience 
with psychoactive substances, no participant had a current or previous DSM/ICD-10 
diagnosis of drug dependence. 
 The volunteers had a mean age of 35 years (26-43). Their past experience with 
psychedelic drugs mainly involved  LSD (11/12), Psilocybe mushrooms (11/12) and 
ayahuasca (8/12). Nine of the participants also had experience with ketamine, six had 
used 2C-B, five had smoked Salvia divinorum, four had taken mescaline-containing 
cacti such as peyote or San Pedro, and two had smoked dimethyltryptamine. At the time 
of the study, eight were using cannabis sporadically (1-2 cigarettes per week). Only four 
were currently tobacco smokers and eleven consumed alcohol in moderate amounts, 
from one or two beers or glasses of wine per day to one per month.  
Prior to participation, all volunteers underwent a complete medical examination 
that included medical history, physical examination, ECG, and standard laboratory tests, 
to confirm good health. Exclusion criteria included a current or past history of 
psychiatric disorders, alcohol or other substance use disorders, evidence of significant 
illness, and pregnancy. The study was conducted in accordance with the Declaration of 
Helsinki and subsequent amendments concerning research in humans and was approved 
by the Sant Pau Hospital Ethics Committee and the Spanish Ministry of Health. All 
volunteers gave their written informed consent to participate. 
 
Drugs 
 Ayahuasca was administered in freeze-dried encapsulated form. The ayahuasca 
batch used in the study was analyzed using a previously described method using liquid 
cromatography-electrospray ionization-tandem mass spectrometry (McIlhenny et al., 
2009). The analysis showed that ayahuasca contained the following alkaloid 
concentrations in mg per gram of freeze-dried material: 6.51 DMT, 13.14 harmine, 1.35 
harmaline and 11.55 THH.  The final dose was calculated individually for each 
participant, so that they received the equivalent of 0.75 mg DMT/kg body weight. The 
dose chosen is of medium intensity and was selected based on data from previous 
studies where it showed robust psychological and physiological effects (Dos Santos et 
al., 2012; Riba et al., 2001b).  Given the alkaloid proportions present in the freeze-dried 
material, at the 0.75 mg/kg DMT dose, participants also ingested 1.51 mg/kg of 
harmine, 0.16 mg/kg of harmaline and 1.33 mg/kg of THH. 
 Ketanserin was administered as the trademark drug Ketensin (ketanserin 
tartrate), at the dose of 40 mg, and placebo capsules contained lactose. 
 
Study design and drug administration 
 The study was conducted according to a double-blind, randomized, balanced, 
crossover design. It involved four experimental sessions one week apart each. Two 
weeks prior to the first experimental session and throughout the study, participants 
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abstained from any psychoactive drugs and medications. Urine was collected for drug 
analysis on each experimental day. Participants tested negative for alcohol, cannabis, 
amphetamines, benzodiazepines, opiates and cocaine. In each session, participants 
received an initial treatment that could be placebo (lactose capsule) or 40 mg ketanserin. 
One hour later, they were administered a second placebo or encapsulated freeze-dried 
ayahuasca. Thus, on each experimental day, participants received one of four different 
treatment combinations: placebo+placebo, placebo+ayahuasca, ketanserin+placebo and 
ketanserin+ayahuasca. 
 Participants remained in the laboratory for 8 hours after which they were 
discharged home. During the first four hours they remained seated in a reclining chair in 
a sound-attenuated and dimly lit room. EEG recordings were conducted before the 
administration of the first treatment (placebo or ketanserin). Ninety minutes after 
administration of the second treatment (ayahuasca or placebo), when the peak 
ayahuasca effects were expected, a second EEG recording was obtained. Four hours 
after administration of the second treatment, when most of the subjective effects of 
ayahuasca had disappeared, the volunteers were allowed to leave the room and were 
asked to answer the subjective effects questionnaires. 
 
Data collection 
EEG recording and processing 
 Three-minute EEG recordings with eyes closed were obtained from 19 standard 
scalp locations (Fp1/2, F3/4, Fz, F7/8, C3/4, Cz, T3/4, T5/6, P3/4, Pz and O1/2). 
Recordings were obtained using a BrainAmp amplifier (Brain Products GmbH, 
Gilching, Germany) before the first treatment (baseline) and 90 minutes after 
administration of the second treatment. Signals were referenced to the averaged mastoid 
electrodes, and vertical and horizontal electrooculograms (EOG) were also obtained for 
artifact minimization and removal. Signals were analogically band-pass filtered between 
0.1 and 45 Hz, digitized with a frequency of 250 Hz.   
 EEG artifact minimization and removal was performed according to a two-step 
procedure before calculating the parameters. First, an ocular artifact minimization step 
was implemented using a previously described method based on blind source separation 
or BSS (Alonso et al., 2010; Romero et al., 2008). The continuous EEG recording was 
then segmented into 5 second epochs. These segments were automatically analyzed for 
saturation, muscular and movement artifacts using the procedure described by Anderer 
and colleagues (Anderer et al., 1992). 
 After computing the two-step artifact preprocessing procedure, spectral analysis 
was performed for all EEG channels. Power spectral density (PSD) functions were 
calculated from artifact-free 5 second epochs by means of a periodogram using a 
Hanning window, and averaged. Averaged PSD functions for each experimental 
situation were quantified into absolute powers in the following frequency bands: delta 
(0.5–3.5 Hz), theta (3.5–7.5 Hz), alpha (7.5-13 Hz), and beta (13-35 Hz). Additionally, 
frequency variability was measured calculating the deviation of the center-of-gravity 
frequency or centroid of the total activity (0.5-35 Hz). 
 
Intracerebral current density calculation 
 The Standardized LORETA (sLORETA) software (Pascual-Marqui et al., 1994) 
was used to estimate the three-dimensional intracerebral current density distribution 
from the voltage values recorded at the scalp. sLORETA estimates a particular solution 
of the non-unique EEG inverse solution restricted to 6239 cortical grey matter voxels 
with a spatial resolution of 0.125 cm3 according to a digitized head model from 
Montreal Neurological Institute (Pasqual-Marqui, 2002). The current density values 
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were estimated based on the EEG cross-spectral matrix and then squared for each voxel 
in the classical frequency bands. 
 
Subjective effect measures  
The psychological effects elicited by the administered treatments were measured 
using a battery of questionnaires on subjective effects: the Hallucinogen Rating Scale 
(HRS), the Addiction Research Center Inventory (ARCI), the Altered States of 
Consciousness Questionnaire (APZ), and a battery of self-administered visual analogue 
scales (VAS).   
 The Hallucinogen Rating Scale (HRS), developed by Strassman and colleagues 
(Strassman et al., 1994), includes 71 items grouped in six subscales: Somaesthesia, 
reflecting somatic effects; Affect, measuring emotional and affective responses; 
Perception, measuring visual, auditory, gustatory, and olfactory experiences; Cognition, 
describing modifications in thought processes or content; Volition, indicating the 
volunteer's capacity to willfully interact with his/her “self” and/or the environment; and 
Intensity, which reflects the strength of the overall experience. The range of scores for 
all scales is 0-4. A validated Spanish version was administered (Riba et al., 2001a). 
 The Addiction Research Center Inventory (ARCI) (Martin et al., 1971) includes  
49 items distributed in five scales or groups: the morphine-benzedrine group (MBG) 
that measures euphoria; the pentobarbital-chlorpromazine-alcohol group (PCAG), that 
measures sedation; the lysergic acid diethylamide scale (LSD), that measures  somatic-
dysphoric effects; the benzedrine group (BG) that measures subjectively experienced 
intellectual efficiency; and the amphetamine scale  (A), which is sensitive to stimulants. 
The range of scores is 0-16 for MBG, -4 to 11 for PCAG, -4 to 10 for LSD, -4 to 9 for 
BG, and 0-11 for A. A validated Spanish version was administered (Lamas et al., 1994). 
 The Altered States of Consciousness questionnaire (“Aussergewöhnliche 
Psychische Zustände”, APZ) (Dittrich, 1998) is composed of  72 items distributed in 
three subscales: Oceanic Boundlessness (“Ozeanische Selbst-entgrenzung”, OSE), to 
measure changes in the sense of time, derealization and depersonalization; Dread of 
Ego-Dissolution (“Angstvolle IchAuflösung”, AIA), for measuring thought disorder and 
decreased body and thought control associated with arousal and anxiety; and Visionary 
Restructuralization (“Visionäre Umstrukturierung”, VUS), referring to visual 
phenomena  such as illusions, hallucinations and synesthesia and to changes in the 
significance of objects. The range of scores is 0-13 for OSE, 0-22 for AIA, and 0-14 for 
VUS. We administered a Spanish version of the questionnaire that had been used  
previously in clinical studies involving psychedelic drugs (Riba et al., 2002b). 
 A battery of self-administered visual analogue scales (VAS) was used to 
retrospectively rate peak effects during the session. Volunteers indicated the intensity of 
the drug effects on a grid of (from 0=no effects to 100=extremely intense effects)  100-
mm horizontal lines. There were ten VAS lines labeled as follows: “Any effect” 
indicated any effect, either physical or psychological, that the volunteer attributed to the 
administered dosage; “Good effects” indicated any effect the volunteer assessed as 
good; “Bad effects” indicated any effect the volunteer assessed as bad; “Liking” 
indicated that the volunteer liked the effects of the administered substance; “Fear” 
indicated apprehension or psychological discomfort; “Time” indicated modifications on 
the perception of time; “Feeling high” indicated any psychological alteration the 
participant attributed to the administered drug; “Changes in external reality” indicated 
changes in perception of external reality; “Loss of contact with external reality” 
indicated separation from the surroundings; and “Visions” indicated visual 
modifications with eyes open or closed.   
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 As mentioned above, despite their recreational drug use, participants had no 
current or past diagnosis of substance use disorders. Consequently, we did not study the 
effects on ayahuasca on specific measures of addiction. 
  
 
Statistical analysis 
EEG data 
 Statistical analysis of EEG recordings was performed following the IPEG 
(International Pharmaco-EEG Group) guidelines for statistical design and analysis of 
pharmacodynamic trials (Ferber et al., 1999). Paired t-tests were carried out for all 
variables and EEG electrodes for assessing drug-induced changes at the 90 minute time 
point. Statistical results were displayed as topographic significance probability maps. 
 
Intracerebral current density data 
 Statistical differences between treatments and placebo were evaluated by paired-
sample t-tests computed for the baseline-corrected and log-transformed LORETA 
power values in each voxel and for each frequency band at the 90 minute time point. To 
correct for multiple comparisons, anon-parametric permutations test (NPT) based on the 
theory of randomization was applied (Nichols and Holmes, 2002). Voxel intensity NPT 
calculates a critical t-value by means of a random sample of all the possible 
permutations to estimate the distribution of the maximum t-statistic. 
 
Subjective effect measures  
 Scores on the HRS, ARCI, APZ, and ARCI questionnaires were analyzed using 
repeated-measures ANOVAs with treatment as factor (placebo+placebo, 
placebo+ayahuasca, ketanserin+placebo, ketanserin+ayahuasca). When significant 
effects were found in the ANOVA, post-hoc pair-wise comparisons between treatments 
were conducted using Student’s t-tests followed by Bonferroni correction. Results were 
considered significant for p values <0.05. 
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Results 
 
Neurophysiological effects 
Topography 
 Figure 1 shows the topographical scalp maps of drug-induced changes in power 
in the different frequency bands following the three active treatments vs. placebo. 
Ayahuasca induced widespread absolute power decreases in the delta, theta and alpha 
frequency bands but did not induce any effects in absolute power the beta frequency 
range. Desynchronization of the EEG was evidenced by the reduction in the alpha 
rhythm and the increase in frequency variability indicated by the deviation of the center-
of-gravity frequency. Ketanserin on its own showed effects opposed to those of 
ayahuasca. It increased absolute power in the delta band at the frontal leads and induced 
more widespread increases in the theta band. No effects were observed in the 
topographical scalp maps in the alpha and beta bands and only marginal decreases were 
seen in the centroid deviation. The administration of ketanserin prior to ayahuasca not 
only counteracted the delta and theta decreases but led to more marked and widespread 
increases in power throughout the scalp in these two frequency bands than those elicited 
by ketanserin alone. Ketanserin completely blocked the alpha decreases induced by 
ayahuasca and reverted the effects on the deviation of the center-of-gravity frequency. 
-------------------------- 
 
Insert Figure 1 about here 
 
-------------------------- 
  
Intracerebral current density data 
 Figure 2 shows the intracerebral analysis of the topographical changes and Table 
1 shows the associated data. The most intense effects observed for ayahuasca were 
current density decreases in the alpha band in posterior brain regions involving the 
occipital, parietal, and temporal lobes. The highest decrease was located in the primary 
visual cortex in Brodmann area (BA) 18. Smaller significant areas were found in the 
frontal lobe. Theta decreases mainly involved the lateral and medial aspects of the 
frontal lobes. The highest decrease was located in the superior frontal gyrus in BA 10. 
Decreases in the delta band were found in the temporal lobe, with the highest decrease 
in the inferior temporal gyrus in BA 20. 
 
-------------------------- 
 
Insert Figure 2 about here 
 
-------------------------- 
  
 Ketanserin on its own did not induce any changes in current source density in 
the alpha and delta bands. However, it induced increases in theta in the frontal lobe, 
specifically in the middle frontal gyrus in BA 6. 
 The administration of ketanserin as pretreatment abolished the alpha decreases 
induced by ayahuasca. Ketanserin also reverted the decreases in theta and led to 
increases in power in this band over extensive areas (see Table 1). The highest increases 
were observed in the frontal lobe, over the precentral gyrus in BA 44. Finally, 
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ketanserin inhibited the delta decreases and led to increases in the occipital lobe and, to 
a lower extent, in the parietal lobe. The highest increase was observed in the cuneus in 
BA 30. 
 
Subjective effects  
HRS 
 Figure 3 shows mean scores on the six subscales of the HRS after the four 
different treatments and Table 2 shows the results of the statistical analyses.  Ayahuasca 
significantly increased scores on all subscales except Volition. Ketanserin on its own 
did not induce any significant changes relative to placebo. When ayahuasca was 
preceded by ketanserin (ketanserin+ayahuasca combination), the 5-HT2A antagonist 
significantly reduced scores on Affect (62% reduction), Perception (56% reduction) and 
Intensity (36% reduction) subcales. An interesting deviant effect was observed in the 
Volition subscale. The ketanserin+ayahuasca combination yielded scores that were 
significantly higher than those after placebo. As shown in the figure, the combination 
had an additive effect, increasing incapacitation further than ayahuasca or ketanserin 
alone (76% increase relative to ayahuasca alone). Ketanserin reduced the scores on the 
somatic and cognitive effects induced by ayahuasca, but these reductions did not reach 
statistical significance. 
 
-------------------------- 
 
Insert Figure 3 about here 
 
-------------------------- 
 
ARCI 
 Figure 3 shows the mean scores on the five subscales of the ARCI, and Table 2 
shows the results of the statistical analyses. Ayahuasca significantly increased scores on 
the MBG, LSD and A subscales. As observed for HRS, ketanserin on its own did not 
induce any significant changes on any subscale.  
When ketanserin preceded ayahuasca, the effects on the MBG subscale were 
significantly blocked (80% reduction), and no statistically significant differences were 
found  between the combination  and placebo. Analogously, ketanserin significantly  
reduced scores on the A subscale (53% reduction). Again, results after 
ketanserin+ayahuasca did not differ from placebo. Scores on the LSD subscale were not 
blocked by ketanserin. Scores after the combination were significantly higher than those 
after placebo and were not significantly different from those after ayahuasca alone. 
Ketanserin not only blocked but reversed the effects of ayahuasca on BG, with 
values falling clearly below those after placebo. This effect of a reduction in 
subjectively perceived intellectual efficiency is consistent with the effects induced by 
the ketanserin+ayahuasca combination on the PCAG scale. Scores on this sedation scale 
were not modified by ayahuasca alone but were markedly increased after the 
combination (≈20 times higher). As shown in the figure, mean values after 
ketanserin+ayahuasca were higher than the mere addition of the effects induced by 
ayahuasca plus those after ketanserin.  
In summary, ketanserin effectively blocked the euphoriant (MBG) and stimulant 
effects of ayahuasca (BG, A) but not its somato-dysphoric effects (LSD). Furthermore, 
it caused marked sedative effects when combined with ayahuasca (PCAG). 
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APZ 
 Mean scores on all subscales of the APZ are shown in Figure 3, and the results 
of the statistical analyses in Table 2.  
Ayahuasca significantly increased scores on all three subscales, whereas 
ketanserin alone did not induce any effects. Scores after ketanserin+ayahuasca were 
significantly lower than those after ayahuasca alone. However, values in the VUS 
subscale measuring visual phenomena were still different from placebo. Thus, although 
ayahuasca effects on the APZ were not completely abolished by ketanserin, they were 
markedly reduced by this drug: 65% reduction for OSE, 55% for AIA and 44% for 
VUS. 
 
VAS 
 Mean scores on all VAS items are shown in Figure 4, and the results of the 
statistical analyses are shown in Table 3.  
 Ayahuasca significantly increased scores on all items except “bad effects”, 
“fear” and “loss of contact with external reality”. Again, ketanserin alone did not induce 
changes in any item. Scores after ketanserin+ayahuasca were significantly lower than 
after ayahuasca alone in the “any effect” (38%), “good effects” (62%), “liking” (61%), 
“time” (13%), “feeling high” (55%), “changes in external reality” (59%), and “visions” 
(38%). However, scores on “any effect”, “time”, “feeling high”, and “visions” were still 
significantly higher than after placebo. Thus, results on the VAS also suggest  
ketanserin partially blocked the subjective effects induced by ayahuasca.  
 
 
-------------------------- 
 
Insert Figure 4 about here 
 
-------------------------- 
 
 
Correlation analysis 
 A correlation analysis was conducted between the ayahuasca-induced current 
density and subjective effects changes. Decreases in alpha correlated with the intensity 
of “visual effects” (r=-0.593, p=0.042) and showed a trend toward significance with the 
APZ-VUS subscale (r=-0.512, p=0.059). These correlations were reduced and 
significance was lost in the ketanserin+ayahuasca combination: VAS “visual effects” 
(r=-0.412, p=0.183)  and APZ-VUS (r=-0.321, p=0.310). Decreases in theta correlated 
with changes in VAS “contact with external reality” (r=-0.591, p=0.043). Again, 
correlation values were reduced and significance was lost after the ketanserin 
pretreatment (r=-0.384, p=0.217). Decreases in delta also correlated with changes in 
contact with external reality (r=-0.724, p=0.008). This correlation was also reduced and 
significance was lost in the ketanserin+ayahuasca combination (r=-0.179, p=0.578). 
Scatter plots for several statistically significant correlations are shown in Figure 5. 
 
-------------------------- 
 
Insert Figure 5 about here 
 
-------------------------- 
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Discussion  
The present study assessed the contribution of 5-HT2A receptors to the 
neurophysiological and subjective effects of ayahuasca in humans. Results showed that  
at the administered dose ayahuasca induced significant psychedelic effects and power 
decreases in the delta-alpha frequency range. Decreases in alpha-band oscillations had 
their source in posterior brain regions and correlated with the intensity of the visual 
modifications induced by ayahuasca. Ketanserin effectively blocked these decreases and 
reduced this correlation, suggesting a prominent role of the 5-HT2A receptor in the 
neurophysiological and visionary effects of ayahuasca. 
The pattern of subjective effects is also in agreement with prior studies with 
ayahuasca. The 0.75 mg DMT/kg body weight ayahuasca dose chosen for the present 
experiment was an intermediate dose used in prior experiments by our group (Dos 
Santos et al., 2012; Riba et al., 2001b). It effectively induced a transient modified state 
of awareness characterized by introspection, increased affect and visual phenomena 
with eyes closed.  
 
The broadband power reductions observed in oscillatory activity replicate results 
in the literature and are consistent with the previous study by our group involving 
ayahuasca at the dose of 0.85 mg/kg body weight and scalp topography analysis (Riba 
et al., 2002a). Our results concerning the source location analysis also agree with a 
previous study in which broad-band power reductions were localized to parieto-
temporo-occipital regions and to a lesser extent to the medial prefrontal/anterior 
cingulate cortex (Riba et al., 2004). This pattern of neurophysiological effects has been 
demonstrated for other psychedelics. Kometer and colleagues, also using EEG, have 
found that psilocybin-induces reductions in spontaneous alpha oscillations (Kometer et 
al., 2013). Muthukumaraswamy and coworkers using magenetoencephalography, a 
technique that measures the magnetic component of brain oscillations, have also 
described that psilocybin decreases power of the magnetic signal in a wide range of 
frequencies, from delta to high gamma (Muthukumaraswamy et al., 2013). 
Energy decreases in brain oscillations suggest an excitatory effect of ayahuasca 
and psychedelics on the cortex. Studies in animals show that psychedelics induce 
excitatory postsynaptic potentials and currents (Kłodzinska et al., 2002). Further, the 
spontaneous alpha rhythm exerts an inhibitory role on the visual cortex in the occipital 
and parietal lobes (Romei et al., 2010, 2008a). Decreases in alpha rhythm are coupled 
with increased regional metabolism (Moosmann et al., 2003). This inverse relationship 
between EEG alpha power and increased cortical activity has also been seen in PET 
studies of blood flow (Buchsbaum et al., 1984), and more recently in studies using 
fMRI. A negative correlation has been found between alpha and BOLD in the anterior 
cingulate and in the parieto-occipital cortex (de Munck et al., 2007; Goldman et al., 
2002; Laufs et al., 2003), a negative relationship that has been extended to the theta and 
beta bands of the EEG (de Munck et al., 2009).  
 Our results support an excitatory effect of ayahuasca on cortical regions 
involved in the processing of visual sensory information (alpha-occipital), memory-
affect (delta-medial temporal lobe or MTL), and cognition-affect (theta-frontolateral 
and frontomedial cortex). Suppression of inhibitory alpha in the visual network, an area 
rich in 5-HT2A receptors (Savli et al., 2012), potentially led to the visionary phenomena 
experienced by participants in the absence of external cues (eyes closed). Analogous to 
our current findings, Kometer and colleagues found that ketanserin blocked psilocybin-
induced reductions in alpha oscillations (Kometer et al., 2013). The marked attenuation 
of alpha decrease and the reduction of visual effects obtained for the 
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ketanserin+ayahuasca pretreatment suggests that both effects are mediated by 5-HT2A 
receptor activation.  
 Increased sensory excitability in posterior visual areas fits the findings of a 
recent study assessing ayahuasca effects on directed functional connectivity (Alonso et 
al., 2015) well. Using Transfer Entropy and Granger Causality, the authors found that, 
under ayahuasca, oscillations in posterior regions increased their influence over signals 
measured at anterior locations. Conversely, oscillatory activity at frontal sources 
decreased its influence over activity at occipital sites. The authors interpreted their 
findings in terms of increased feed-forward or bottom-up information transfer and 
decreased feed-back or top-down control.  Our findings would support 5-HT2A agonism 
as a key mechanism in the modification of brain dynamics induced by ayahuasca 
(McKenna and Riba, 2015). 
 Ayahuasca administration in the present study led to significant increases in 
measures of affective modifications, in agreement with previous results (Dos Santos et 
al., 2011; Riba et al., 2006, 2003b). We also found EEG power reductions in areas 
associated with affective processing, i.e., the MTL and the medial frontal lobe/anterior 
cingulate cortex (ACC). Power decreases and increased blood flow in these regions had 
been reported previously using LORETA (Riba et al., 2004) and SPECT (Riba et al., 
2006), respectively. The amygdala in the MTL and the ACC are key hubs of affective 
processing. The amygdala is associated with fear and emotional arousal, whereas the 
ACC and neighboring medial frontal areas integrate emotion and cognition. Effects at 
these levels have been proposed to underlie the therapeutic potential of ayahuasca (Soler 
et al., 2015). Ketanserin led to a 62% reduction in the HRS-Affect, subscale, an 80% 
reduction in the ARCI-MBG (positive mood/euphoria), and antagonized the delta and 
theta decreases in these regions. These results indicate a prominent role of 5-HT2A 
activation in the affective effects of ayahuasca and warrant future studies of the 
cognitive aspects of emotional processing during the ayahuasca experience. 
 
An unexpected finding was that while ketanserin decreased the overall intensity 
of the subjective experience, blockade was only partial. This finding contrasts with 
more intense inhibition found in studies involving psilocybin. Vollenweider and 
colleagues, for example,  administered the same ketanserin dose (40 mg) prior to a high 
oral dose of 25 mg psilocybin and obtained reductions between 75% and 98% in the 
intensity of visual effects (Vollenweider et al., 1998). Examining the individual data in 
our study we found that two participants had a deviant pattern in their scores, with 
higher scores (60 and 100 mm, respectively) on the VAS-Visions item after the 
ketanserin+ayahuasca combination than after ayahuasca alone (14 and 74 mm, 
respectively). If these two participants are removed from the sample, the global mean 
for this item rises to 60 mm after ayahuasca and drops to 27 mm after the combination. 
However, even if we removed these two outliers, the inhibition of visual effects in our 
study would still be far from the suppression levels attained by Vollenweider.  
One possible explanation for these unexpected results is that DMT interacts with 
other receptors in addition to 5-HT2A. Indolealkylamines such as DMT and psilocybin 
also show agonist effects at the 5-HT1A sites. These predominantly pre-synaptic 
receptors are present in large amounts in the raphe nuclei and their activation suppresses 
serotonin release. They are also present in the visual cortex, but they exert an inhibitory 
effect (Gerstl et al., 2008; Moreau et al., 2010). It is therefore doubtful that increased 5-
HT1A activation by DMT in the presence of ketanserin increases visual phenomena. 
However, 5-HT1A agonism may have been responsible for the marked sedation 
experienced by participants when given the combination (indicated for instance by the 
high score on the ARCI-PCAG subscale obtained for the combination). Reductions in 
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vigilance and attentional performance have been observed for the combination of 
ketanserin plus psilocybin (Carter et al., 2005). Theta power increases, as seen in our 
experiment for ayahuasca+ketanserin, are the characteristic effects of the anxiolytic -
HT1A agonist buspirone (Barbanoj, MJ et al., 1994). 
DMT shows additional mechanistic differences from other psychedelics, which 
might account for the partial blockade of the observed effects. For instance, in contrast 
to the prototypical 5-HT2A agonist 2,5-dimethoxy-4-iodoamphetamine (DOI), DMT 
induces a weak behavioral head twitch response in animals (Carbonaro et al., 2015) and 
unlike LSD, it does not seem to lead to acute tolerance (Dos Santos et al., 2012; 
Strassman et al., 1996). Molecular mechanisms specific to DMT are agonism at the 
trace amine associated receptor (TAAR) (Bunzow et al., 2001); the fact that DMT is a 
substrate of both the serotonin and the vesicle monoamine transporters (Cozzi et al., 
2009); and that it modulates the intracellular sigma-1 receptor (Fontanilla et al., 2009). 
 The sigma-1 receptor is a chaperone protein localized in the endoplasmic 
reticulum. It is involved in the regulation of many other proteins and signaling pathways 
and it has a protective role in cell survival (Chu and Ruoho, 2016; Hayashi and Su, 
2007). It is also involved in neural plasticity, as it promotes dendritic spine and synapse 
formation (Tsai et al., 2009). Abnormal function of the sigma-1 receptor has been 
associated with various neurodegenerative disorders (Tsai et al., 2014). It is noteworthy 
that several antidepressants, such as fluvoxamine and sertraline show high affinity for 
this receptor (Rousseaux and Greene, 2015). It can be speculated that sigma-1 activation 
by DMT could play a role mediating the antidepressant effects found for ayahuasca 
(Osório et al., 2015; Sanches et al., 2015). These mechanisms should be addressed in 
future studies. 
As a limitation of the study we would like to mention that volunteer recruitment 
emphasized previous experience with psychedelic drugs. Although participants had no 
present or previous diagnosis of drug dependence, detailed information on the dose, 
frequency and duration of consumption of other drugs was not collected. 
To sum up, the present study assessed the contribution of the 5-HT2A receptor to 
the neurophysiological and psychological effects of ayahuasca. Ayahuasca induced an 
intense inhibitory effect on alpha oscillations in the parieto-occipito-temporal cortex 
that correlated with visual phenomena, a hallmark of the ayahuasca experience. The 
selective 5-HT2A receptor antagonist ketanserin effectively inhibited neurophysiological 
modifications, reduced the correlation between alpha and the visual effects, and 
attenuated the intensity of the subjective experience. These findings suggest that despite 
the chemical complexity of ayahuasca, 5-HT2A activation may especially contribute to 
its visual perceptual effects. Future studies should assess the role of other molecular 
mechanisms, such as sigma-1 agonism, in the perceptual, affective and cognitive effects 
of DMT and ayahuasca. 
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Figure 1: Significance probability maps showing differences between the three 
administered active treatments and placebo. These maps show changes at the 19 leads 
placed over the scalp. They depict modifications in absolute power in three different 
frequency bands and in the deviation of the center-of-gravity frequency (centroid 
deviation). The four rows from top to bottom show: 1) changes in delta (0.5-3.5 Hz) 
power; 2) changes in theta (3.5-7.5 Hz) power; 3) changes in alpha (7.5-13 Hz) power; 
4) changes in centroid deviation. The vertex view shows the nose at the top, the left ear 
to the left, the right ear to the right. Electrode positions are indicated by white dots. 
Warm colors denote increases and cold colors decreases at the significance level 
indicated by the color bar. 
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Figure 2: Effects of the three administered active treatments vs. placebo on current 
source density. These maps show the intracerebral current density distribution 
associated with energy changes recorded at the scalp. The color coding represents 
statistical significance above a critical value calculated using the non-parametric 
Holmes permutation test to correct for multiple comparisons. Results are shown for the 
delta band (0.5-3.5 Hz) in the top rows, the theta band (3.5-7.5 Hz) in the middle rows, 
and the alpha band (7.5-13 Hz) in the bottom rows. Cold colors denote significant 
decreases and warm colors significant increases compared to placebo (placebo+placebo) 
after Holmes correction (p < 0.05). The color bars indicate the critical t-value for each 
frequency band and statistical comparison.  
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Figure 3: Mean scores on the Hallucinogen Rating Scale (HRS), Addiction Research 
Center Inventory (ARCI) and Altered States of Consciousness (Aussergewöhnliche 
Psychische Zustände, APZ) subscales for the three active treatments administered and 
placebo. Error bars denote 1 standard error of mean (n=12). Significant differences from 
placebo are denoted as * at p<0.05, ** at p<0.01, and *** at p<0.001. Significant 
differences between ayahuasca alone and ayahuasca after pretreatment with ketanserin 
are denoted as † at p<0.05, †† at p<0.01, and ††† at p<0.001. All pair-wise 
comparisons are shown after Bonferroni correction. Green: placebo, red: ayahuasca, 
yellow: ketanserin, blue: ketanserin+ayahuasca. The abbreviations indicate: Pla: 
placebo, Aya: Ayahuasca equivalent to 0.75 mg DMT /Kg body weight, Ket: 40 mg 
ketanserin, Aya+Ket: combined treatment ayahuasca + ketanserin. ARCI – A: 
Amphetamine scale; BG: Benzedrine-Group; MBG: Morphine-Benzedrine-Group; 
PCAG: Pentobarbital-Chlorpromazine-Alcohol-Group; LSD: Lysergic acid 
diethylamide scale. APZ-OSE: Oceanic boundlessness , AIA: Dread of ego dissolution , 
VUS:  Visionary restructuralization. 
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Figure 4:  Mean scores on the visual analogue scales (VAS) items for the three active 
treatments administered and placebo. Error bars denote 1 standard error of mean (n=12). 
AE: any effect; GE: good effects; BE: bad effects; LK: liking; FE: fear; TI: 
modifications of time perception; HI: feeling “high”; RE: changes in external reality; 
CO: loss of contact with external reality; VI: visions. Significant differences from 
placebo are denoted as * at p<0.05, ** at p<0.01, and *** at p<0.001. Significant 
differences between ayahuasca alone and ayahuasca after pretreatment with ketanserin 
are denoted as † at p<0.05, †† at p<0.01, and ††† at p<0.001. All pair-wise 
comparisons are shown after Bonferroni correction. Green: placebo, red: ayahuasca, 
yellow: ketanserin, blue: ketanserin+ayahuasca. 
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Figure 5: Scatter plots showing the relationship between current density changes and  
the intensity of subjective effects as measured by visual analogue scales (VAS) and 
expressed in millimeters from 0 to 100. Top panel: decreases in alpha and the VAS 
“visual effects” (r=-0.593, p=0.042); Middle panel: decreases in theta and the VAS 
“contact with external reality” (r=-0.591, p=0.043); and Bottom panel: decreases in 
delta and the VAS “contact with external reality” (r=-0.724, p=0.008). 
 
